Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human VEGFC Antibodies:
anti-Mouse (Murine) VEGFC Antibodies:
anti-Rat (Rattus) VEGFC Antibodies:
Go to our pre-filtered search.
Human Polyclonal VEGFC Primary Antibody for IHC (fro), IHC (p) - ABIN258871
Zampell, Yan, Avraham, Daluvoy, Weitman, Mehrara: HIF-1α coordinates lymphangiogenesis during wound healing and in response to inflammation. in FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2012
Show all 8 Pubmed References
Human Polyclonal VEGFC Primary Antibody for IF (p), IHC (p) - ABIN731723
Zhuo, Jia, Song, Lu, Ding, Wang, Song, Fu, Luo: The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis. in Clinical cancer research : an official journal of the American Association for Cancer Research 2012
Show all 3 Pubmed References
Human Monoclonal VEGFC Primary Antibody for ICC, IHC (fro) - ABIN438679
Moussai, Mitsui, Pettersen, Pierson, Shah, Suárez-Fariñas, Cardinale, Bluth, Krueger, Carucci: The human cutaneous squamous cell carcinoma microenvironment is characterized by increased lymphatic density and enhanced expression of macrophage-derived VEGF-C. in The Journal of investigative dermatology 2010
Show all 2 Pubmed References
Human Polyclonal VEGFC Primary Antibody for FACS, IHC (p) - ABIN650694
Yan, Zhu, Yu, Ji, Zhang, Ji, Yan, Chen, Liu, Yin, Lin: Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis. in World journal of gastroenterology : WJG 2004
Show all 3 Pubmed References
Rat (Rattus) Polyclonal VEGFC Primary Antibody for IP, ELISA - ABIN1589911
Maertens, Erpicum, Detry, Blacher, Lenoir, Carnet, Péqueux, Cataldo, Lecomte, Paupert, Noel: Bone marrow-derived mesenchymal stem cells drive lymphangiogenesis. in PLoS ONE 2014
Vegfc acts through ERK (show MAPK1 Antibodies) to induce sprouting and differentiation of trunk lymphatic progenitors.
data not only reveal a non-canonical function of Mt2 (show MT2 Antibodies) in angiogenesis, but also propose Mt2 (show MT2 Antibodies) as a novel regulator of vegfc expression.
Vegfc signaling increases mafba (show MAFB Antibodies) expression to control downstream transcription
Vegfc is dispensable for facial lymphatic sprouting but not for the complete development of the facial lymphatic network.
In the embryo, phenotypes driven by increased Vegfc are suppressed in the absence of Ccbe1 (show CCBE1 Antibodies), and Vegfc-driven sprouting is enhanced by local Ccbe1 (show CCBE1 Antibodies) overexpression. Moreover, Vegfc- and Vegfr3 (show FLT4 Antibodies)-dependent Erk (show MAPK1 Antibodies) signaling is impaired in the absence of Ccbe1 (show CCBE1 Antibodies).
Vegfc has an essential role in lymphangiogenesis [review]
The parallel growth of motoneuron axons with the dorsal aorta depends on Vegfc/Vegfr3 (show FLT4 Antibodies) signaling in zebrafish.
Vegfc acts in two distinct modes during development: as a paracrine factor secreted from arteries to guide closely associated lymphatic vasculature and as an autocrine factor to drive migratory persistence during angiogenesis.
Rspo1-Wnt-VegfC-Vegfr3 signaling plays a crucial role as an endothelial-autonomous permissive cue for developmental angiogenesis.
Here, we show that vascular endothelial growth factor C (Vegfc), an angiogenic as well as a lymphangiogenic factor, is unexpectedly involved in this process in zebrafish.
VEGF-C and VEGF-C156S genes have roles in the pro-lymphangiogenic growth factor therapy of lymphedema
Transcription of the vascular endothelial growth factor C gene (VEGF-C) and translation of the corresponding protein were significantly up-regulated in swine umbilical vein endothelial cells with classical swine fever virus acute infection.
No difference in bioactivity was detected between porcine relaxin-1 (show RLN1 Antibodies) and recombinant human relaxin-2 (show RLN1 Antibodies) in either mice or rats.
During progressive ischemia, functional and metabolic benefits of intramyocardial VEGF-C gene transfer were apparent. VEGF-C-induced collateral formation occurred at the site of gene transfer
document for the first time that CCL5 (show CCL5 Antibodies) induces tumor lymphangiogenesis by the induction of VEGF-C in human cancer cells.
Data suggest that the BRG1 (show SMARCA4 Antibodies)/STAT3 (show STAT3 Antibodies)/VEGFC in tumor-associated lymphangiogenesis might lead to the discovery of novel therapeutic targets in the treatment of cancers with BRG1 (show SMARCA4 Antibodies) loss of function.
Studied the effect of recombinant human vascular endothelial growth factor (VEGF)-C on lymphangiogenesis, inflammation, and fibrosis in the mouse kidney using the unilateral ureteral obstruction (UUO); lymphangiogenesis was significantly induced in the UUO+VEGF-C group. In lymphatic endothelial cells, VEGF-C increased the activity and proliferation of such cells and expression of VCAM-1.
In multivariate analysis, only serum VEGF-A (show VEGFA Antibodies) correlated to diabetes duration, whereas VEGF-C only correlated to HbA1c and fasting blood glucose.
This study reports that human dendritic cells produce VEGF-C, a cytokine with potent pro-lymphangiogenic activity when stimulated with IFN-gamma (show IFNG Antibodies)
Association of coexpressed high levels of VEGF-C and active MMP-9 (show MMP9 Antibodies) with lymphatic spreading and local invasiveness of Papillary thyroid carcinoma (PTC (show F9 Antibodies)) suggests their potential usefulness as predictive biomarkers of aggressive PTC (show F9 Antibodies) behavior.
Data show that VEGF-C, VEGF-D (show Figf Antibodies), and VEGFR-3 (show FLT4 Antibodies) were expressed in a substantial percentage of breast carcinomas.
By treating LECs with VEGF (show VEGFA Antibodies)-C156S and analyzing subsequent changes in gene expression, we identified several 'immediate early (show JUN Antibodies)' transcription factors that showed a rapid transient upregulation VEGFR-3 (show FLT4 Antibodies) stimulation. these results reveal an important and unanticipated role of HOXD10 (show HOXD10 Antibodies) in the regulation of VEGFR-3 (show FLT4 Antibodies) signaling in lymphatic endothelial cells, and in the control of lymphangiogenesis and permeability.
In colon cancer samples, there was a positive correlation between the expression of integrin alpha4 and VEGF-C. Integrin alpha4 and VEGF-C were significantly associated with the clinicopathological parameters (LMVD, Duke's stage, and lymph node metastasis). patients with high integrin alpha4 or VEGF-C expression had significantly shorter overall survival and tumor-free survival time.
High VEGFC expression is associated with angiogenesis and lymphangiogenesis.
lymphangiogenesis is regulated by two distinct proteolytic mechanisms of ligand activation: one in which VEGFC activation by ADAMTS3 (show Adamts2 Antibodies) and CCBE1 (show CCBE1 Antibodies) spatially and temporally patterns developing lymphatics, and one in which VEGFD (show Figf Antibodies) activation by a distinct proteolytic mechanism may be stimulated during inflammatory lymphatic growth
These results reveal an unexpected role for VEGF-C, a major lymphangiogenic growth factor, in the transition to fetal liver erythropoiesis.
Results suggest that interleukin-6 (IL-6 (show IL6 Antibodies)) increases VEGF-C induction and lymphangiogenesis may involve, at least in part, Src (show SRC Antibodies)-FAK (show PTK2 Antibodies)-STAT3 (show STAT3 Antibodies) cascade in lymphatic endothelial cells (LECs).
Data show that heparanase-1 (HPA-1 (show HPSE Antibodies)) induced shedding of heparan sulfate chain from syndecan-1 (SDC-1 (show SDC1 Antibodies)) facilitated the release of vascular endothelial growth factor C (VEGF-C) from SDC-1 (show SDC1 Antibodies)/VEGF-C complex into the medium of hepatocarcinoma cell.
Data show that in the MCF-7 breast cancer cell line, only MT1X (show MT1X Antibodies) metallothioneins (MTs (show NEU2 Antibodies)) positively correlated with vascular endothelial growth factor C (VEGFC).
The findings in this study strongly suggest the following: i) that VEGF-C promotes the proliferative activity and migratory ability of mesenchymal stem cell ; and ii) VEGF-C and Tgfb (show TGFB1 Antibodies) reciprocally regulate mesenchymal stem cell commitment to differentiation into lymphatic endothelial or osteoblastic phenotypes, respectively.
The authors show that VEGF-C is necessary for perinatal lymphangiogenesis, but required for adult lymphatic vessel maintenance only in the intestine.
MT1-MMP (show MMP14 Antibodies) directly cleaves LYVE-1 (show LYVE1 Antibodies) on lymphatic endothelial cells to inhibit LYVE-1 (show LYVE1 Antibodies)-mediated lymphangiogenic responses and restrains the production of VEGF-C.
HA increases lymphangiogenesis in renal fibrosis model and also stimulates vascular endothelial cell growth factor (show FGF1 Antibodies)-C production from macrophages through Toll-like receptor 4 (show TLR4 Antibodies)-dependent signal pathway
Results showed that the VEGF-C/VEGFR-3 (show FLT4 Antibodies) system underlies the protective effect of ischemic preconditioning against forebrain ischemia in the mouse hippocampus
The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis and endothelial cell growth, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor D.
vascular endothelial growth factor C
, vascular endothelial growth factor c
, FLT4 ligand DHM
, vascular endothelial growth factor-related protein
, flt4 ligand
, vascular endothelial growth factor C isoform 129
, vascular endothelial growth factor C isoform 184